Q3 25 EPS
$0.23
BEAT +48.67%
Est. $0.15
Q3 25 Revenue
$1.36B
BEAT +2.53%
Est. $1.33B
vs S&P Since Q3 25
+1.3%
BEATING MARKET
SEM +12.0% vs S&P +10.7%
Market Reaction
Did SEM Beat Earnings? Q3 2025 Results
Select Medical delivered a standout third quarter, with earnings per share of $0.23 beating the $0.15 consensus estimate by 48.67%, a margin that signals genuine operational momentum rather than a one-time lift. Revenue came in at $1.36 billion, clea… Read more Select Medical delivered a standout third quarter, with earnings per share of $0.23 beating the $0.15 consensus estimate by 48.67%, a margin that signals genuine operational momentum rather than a one-time lift. Revenue came in at $1.36 billion, clearing estimates by 2.53%, though the top line reflects a 22.6% year-over-year decline as the company laps results that previously included Concentra, now spun off as a separate entity following a tax-free distribution in November 2024. The cleaner, more focused post-acute and rehabilitation business showed real underlying strength: rehabilitation hospitals were the standout, with revenue climbing 16.2% to $328.61 million on 11.2% higher admissions and an occupancy rate of 83%, while the critical illness recovery segment expanded margins to 9.2% from 8.7% despite modest volume softness. Outpatient rehabilitation did face cost pressure, with Adjusted EBITDA margins narrowing to 7.4% from 9.1%. Looking ahead, management raised its full-year EPS guidance to $1.14–$1.24 while reaffirming revenue of $5.30 billion–$5.50 billion, underscoring confidence in the company's post-separation trajectory.
Key Takeaways
- • Rehabilitation hospital segment revenue grew 16.2% driven by 2 additional hospitals, 11.1% more patient days, and 11.2% higher admissions
- • Critical illness recovery hospital revenue per patient day increased 6.6% to $2,287
- • Outpatient rehabilitation visits increased 5.5% year-over-year
- • Rehabilitation hospital occupancy improved to 83% from 82%
- • Critical illness recovery hospital Adjusted EBITDA margin expanded to 9.2% from 8.7%
SEM YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
SEM Revenue by Segment
With YoY comparisons, source: SEC Filings
SEM Earnings Trends
SEM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
SEM EPS Trend
Earnings per share: estimate vs actual
SEM Revenue Trend
Quarterly revenue: estimate vs actual
SEM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.46 | $0.36 | -21.00% | $1.42B | +0.49% |
| Q4 25 MISS FY | $0.23 | $0.16 | -31.06% | $1.40B | +2.39% |
| FY Full Year | $1.23 | $1.16 | -5.55% | $5.45B | +0.60% |
| Q3 25 BEAT | $0.15 | $0.23 | +48.67% | $1.36B | +2.53% |
| Q2 25 BEAT | $0.24 | $0.32 | +35.19% | $1.34B | -0.66% |
| Q1 25 MISS | $0.45 | $0.44 | -1.54% | $1.35B | -3.02% |